Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuankai Shi

Showing results (51-60 of 347) with videos related to

Pageof 35
Sort By:
Future Oncology (London, England)|February 13, 2015
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancerFenlai Tan, Yuankai Shi, Yinxiang Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 10, 2015
Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancerYihebali Chi, Jianliang Yang, Sheng Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|October 15, 2015
[A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma]Yunxia Tao, Suyi Kang, Liqiang Zhou, et al.
BMC Cancer|April 5, 2023
Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancerLiling Huang, Yu Feng, Tongji Xie, et al.
Investigational New Drugs|April 18, 2022
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysisYunxia Tao, Yu Zhou, Le Tang, et al.
Thoracic Cancer|November 12, 2015
Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trialYuankai Shi, Yi Hu, Xingsheng Hu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 18, 2002
[Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy]Aiping Zhou, Yuankai Shi, Fengyi Feng, et al.
Current Cancer Drug Targets|October 19, 2018
Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal MetastasesYuanyuan Song, Peng Liu, Yu Huang, et al.
Oncology Reports|September 24, 2015
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancerLin Lin, Haibo Lin, Lin Wang, et al.
Thoracic Cancer|August 29, 2018
Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapyShengyu Zhou, Lijie Zuo, Xiaohui He, et al.
Pageof 35

Showing results (51-60 of 347) with videos related to

Sort By:
Pageof 35
Future Oncology (London, England)|February 13, 2015
Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancerFenlai Tan, Yuankai Shi, Yinxiang Wang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|July 10, 2015
Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancerYihebali Chi, Jianliang Yang, Sheng Yang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|October 15, 2015
[A analysis of the outcome and prognostic factors in 415 patients with Hodgkin lymphoma]Yunxia Tao, Suyi Kang, Liqiang Zhou, et al.
BMC Cancer|April 5, 2023
Incidence, survival comparison, and novel prognostic evaluation approaches for stage iii-iv pulmonary large cell neuroendocrine carcinoma and small cell lung cancerLiling Huang, Yu Feng, Tongji Xie, et al.
Investigational New Drugs|April 18, 2022
Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysisYunxia Tao, Yu Zhou, Le Tang, et al.
Thoracic Cancer|November 12, 2015
Cisplatin combined with irinotecan or etoposide for untreated extensive-stage small cell lung cancer: A multicenter randomized controlled clinical trialYuankai Shi, Yi Hu, Xingsheng Hu, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|December 18, 2002
[Contamination with minimal residual disease in autologous peripheral stem cell collected from Non-Hodgkin's lymphoma patients treated with high-dose therapy]Aiping Zhou, Yuankai Shi, Fengyi Feng, et al.
Current Cancer Drug Targets|October 19, 2018
Osimertinib Quantitative and Gene Variation Analyses in Cerebrospinal Fluid and Plasma of a Non-small Cell Lung Cancer Patient with Leptomeningeal MetastasesYuanyuan Song, Peng Liu, Yu Huang, et al.
Oncology Reports|September 24, 2015
miR-130a regulates macrophage polarization and is associated with non-small cell lung cancerLin Lin, Haibo Lin, Lin Wang, et al.
Thoracic Cancer|August 29, 2018
Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapyShengyu Zhou, Lijie Zuo, Xiaohui He, et al.
Pageof 35